Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256385 | 0.99 | HTR4 (0.52) | HTR4DRD2CYP1A2CYP3A4ADRA2A | |
| SCHEMBL4893614 | 0.92 | HTR4 (0.50) | HTR4DRD2CYP1A2CYP3A4ADRA2A | |
| SCHEMBL8292927 | 0.87 | HTR4 (0.57) | HTR4DRD2CYP1A2CYP3A4ADRA2A | |
| SCHEMBL4883983 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL5522497 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL5522502 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL5524758 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL5529804 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL4892940 | 0.85 | HTR4 (0.71) | HTR4DRD2 | |
| SCHEMBL4895970 | 0.85 | HTR4 (0.70) | HTR4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070944-A1 | Novel methods using aminobenzoic acid compounds | EISAI CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070015789-A1 | Novel methods using aminobenzoic acid compounds | EISAI CO., LTD. (JP) | 2007-01-18 | — | — | US | disclosed |
| WO-2005007600-A2 | NOVEL METHODS USING AMINOBENZOIC ACID COMPOUNDS | EISAI CO., LTD. (JP) | 2005-01-27 | — | — | WO | disclosed |
| EP-0554794-B1 | Aminobenzoic acid derivatives | EISAI CO LTD (JP) | 1998-07-29 | — | — | EP | disclosed |
| US-5631402-A | ETHERIFYING 4-AMINO-5-HALOGEN-SALICYLIC ACID WITH ALKYNOL IN PRESENCE OF TRIPHENYLPHOSPHINE AND DIALKYLAZOCARBOXYLATE | EISAI CO., LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5599972-A | GASTROINTESTINAL DISORDERS | EISAI CO., LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5578603-A | TREATMENT FOR ALZHEIMER*S DISEASE, GAASTROINTRESTINAL DISORDERS | EISAI CO., LTD. (JP) | 1996-11-26 | — | — | US | disclosed |
| US-5389643-A | Antiseerotonine, anticholinergic agents | EISAI CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0554794-A1 | Aminobenzoic acid derivatives | Eisai Co., Ltd. (JP) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015789-A1 | Novel methods using aminobenzoic acid compounds | GRIN2B, HTR5A, AADAT | ACHE 1090/4885HTR4 133/4885DRD2 2122/4885 |
| US-20080070944-A1 | Novel methods using aminobenzoic acid compounds | GRIN2B, HTR5A, AADAT | ACHE 1090/4885HTR4 133/4885DRD2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.